Literature DB >> 8989348

Considerations related to the use of recombinant human growth hormone in children. American Academy of Pediatrics Committee on Drugs and Committee on Bioethics.

.   

Abstract

Since 1985 molecular biology techniques have made possible the synthetic synthesis of pure human growth hormone in potentially unlimited amounts. With this increased availability, its use in patients other than children with growth hormone deficiency has been associated with clinical and ethical questions. This statement presents an analysis of the current status of the use of human growth hormone in children.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8989348     DOI: 10.1542/peds.99.1.122

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  11 in total

Review 1.  Management of short stature.

Authors:  Shayne P Taback; Heather J Dean; Elizabeth Elliott
Journal:  West J Med       Date:  2002-05

2.  Effect of Growth Hormone Therapy on Height Velocity in Korean Children with Idiopathic Short Stature: A Phase III Randomised Controlled Trial.

Authors:  Woo Yeong Chung; Han-Wook Yoo; Jin Soon Hwang; Cheol Woo Ko; Ho-Seong Kim; Dong-Kyu Jin; Kee-Hyoung Lee; Heon-Seok Han; Premila Paranchothy; Byung-Kyu Suh
Journal:  Horm Res Paediatr       Date:  2018-08-15       Impact factor: 2.852

3.  Growth Disorders.

Authors:  Meena P Desai
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 4.  Dilemmas of growth hormone treatment for GH deficiency and idiopathic short stature: defining, distinguishing, and deciding.

Authors:  Julia G Halas; Adda Grimberg
Journal:  Minerva Pediatr       Date:  2020-04-09       Impact factor: 1.312

5.  Sex differences in patients referred for evaluation of poor growth.

Authors:  Adda Grimberg; Jessica Katz Kutikov; Andrew J Cucchiara
Journal:  J Pediatr       Date:  2005-02       Impact factor: 4.406

6.  Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA).

Authors:  A Ciresi; F Cicciò; M C Amato; C Giordano
Journal:  J Endocrinol Invest       Date:  2015-05-27       Impact factor: 4.256

7.  Managing idiopathic short stature: role of somatropin (rDNA origin) for injection.

Authors:  J Paul Frindik; Stephen F Kemp
Journal:  Biologics       Date:  2010-06-24

8.  The evaluation and followup of children referred to pediatric endocrinologists for short stature.

Authors:  David Wyatt; Katrina L Parker; Stephen F Kemp; Jane Chiang; D Aaron Davis
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-24

Review 9.  "Anything you can do, I can do bigger?": the ethics and equity of growth hormone for small normal children.

Authors:  D G Gill
Journal:  Arch Dis Child       Date:  2006-03       Impact factor: 3.791

Review 10.  Growth hormone therapy and quality of life in adults and children.

Authors:  Deborah J Radcliffe; Joseph S Pliskin; J B Silvers; Leona Cuttler
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.